High-Cost Sickle Cell Gene Therapies: A New Payment Model Challenge for Insurers and Medicaid Programs

High-cost gene therapies for sickle cell disease (SCD) are pushing insurers and Medicaid programs to find new payment models to ensure equitable patient access and manage financial constraints. With the approval of Casgevy, a gene therapy for SCD, and other high-priced treatments on the horizon, payers are grappling with the affordability and accessibility of these life-changing therapies.